anti tumor pralatrexate t cell lymphoma

Pralatrexate (52853-40-4) Pralatrexate is an injectable DHFR inhibitor approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This antineoplastic agent works by inhibiting folate enzymes DHFR and thymidylate synthase, representing a well-validated approach to cancer treatment. Product Specifications Product Name: Pralatrexate CAS No.: 52853-40-4 Assay: 98.9% Specification: CP, EP, In-house, as required Molecular Formula: C23 H23

6-(Bromomethyl)-2,4-pteridinediamine hydrobromide (52853-40-4) 6-(Bromomethyl)-2,4-pteridinediamine hydrobromide is a potent inhibitor of the enzyme nitroaldolase (EC 1.2.1.22) and has been shown to inhibit cell growth in murine leukemia cells. It serves as a key intermediate in the synthesis of Pralatrexate. Product Specifications Product Name: 6-(Bromomethyl)-2,4-pteridinediamine hydrobromide CAS No.: 52853-40-4 Assay: 98% End Use: Pralatrexate Intermediate Molecular